Xeltis is a clinical-stage company developing medical devices enabling cardiovascular restoration. Xeltis medical device platform comprises the first-ever bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR): the natural restoration of the complex body part they replace upon implantation. www.xeltis.com Please note: Xeltis cannot provide any information to individual patients in relations to clinical trials, due to privacy and clinical practice regulations; please contact the relevant trial centres for any enquiries. www.xeltis.com